Imunon’s (IMNN) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Imunon (NASDAQ:IMNN) in a report released on Wednesday,Benzinga reports. The firm currently has a $14.00 price objective on the stock.

Separately, D. Boral Capital reissued a “buy” rating and issued a $29.00 price target on shares of Imunon in a research report on Monday.

Imunon Price Performance

Shares of IMNN opened at $1.04 on Wednesday. The stock’s fifty day moving average price is $0.90 and its two-hundred day moving average price is $0.92. Imunon has a 1 year low of $0.64 and a 1 year high of $3.65. The firm has a market cap of $15.21 million, a PE ratio of -0.55 and a beta of 1.96.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Imunon stock. Geode Capital Management LLC grew its position in shares of Imunon, Inc. (NASDAQ:IMNN) by 10.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 139,505 shares of the company’s stock after purchasing an additional 13,570 shares during the period. Geode Capital Management LLC owned about 0.96% of Imunon worth $133,000 at the end of the most recent reporting period. Institutional investors own 4.47% of the company’s stock.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.